CYTOF (Altamira Therapeutics) DeferredTaxAndRevenue : $0.00 Mil (As of Dec. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Altamira Therapeutics DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Altamira Therapeutics's current deferred tax and revenue for the quarter that ended in Dec. 2024 was $0.00 Mil.

Altamira Therapeutics DeferredTaxAndRevenue Historical Data

The historical data trend for Altamira Therapeutics's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Altamira Therapeutics DeferredTaxAndRevenue Chart

Altamira Therapeutics Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

DeferredTaxAndRevenue

Get a 7-Day Free Trial

0.21

Altamira Therapeutics Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
DeferredTaxAndRevenue	Get a 7-Day Free Trial															-	-	0.21	-	-

Altamira Therapeutics DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Altamira Therapeutics's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Altamira Therapeutics Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Altamira Therapeutics Ltd (OTCPK:CYTOF) » Definitions » DeferredTaxAndRevenue

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Church Street, Clarendon House, Hamilton, BMU, HM11

Website

https://www.altamiratherapeutics.com

Altamira Therapeutics Ltd is dedicated to developing therapeutics that address unmet medical needs. It is active in RNA therapeutics, allergy, viral infections, and inner ear disorders. Its product Bentrio, is a drug-free nasal spray for personal protection against airborne viruses and allergens. The company's OligoPhore / SemaPhore platform is a versatile system that allows the complexation of therapeutic RNAs with a proprietary peptide to form a nanoparticle formulation. This formulation allows for the delivery of therapeutic RNA by systemic administration to tissues affected by leaky vasculature, a hallmark of solid tumors and certain inflammatory conditions.